TY - JOUR T1 - A Biomarker Panel Increases the Diagnostic Performance for Epithelial Ovarian Cancer Type I and II in Young Women JF - Anticancer Research JO - Anticancer Res SP - 957 LP - 965 VL - 36 IS - 3 AU - PIA LEANDERSSON AU - GRIGORIOS KALAPOTHARAKOS AU - EMIR HENIC AU - HENRIK BORGFELDT AU - MAX PETZOLD AU - GUNILLA HØYER-HANSEN AU - CHRISTER BORGFELDT Y1 - 2016/03/01 UR - http://ar.iiarjournals.org/content/36/3/957.abstract N2 - Background/Aim: To assess preoperative blood levels of a biomarker panel in relation to the new classification system of epithelial ovarian cancer (EOC) type I and II. Patients and Methods: Preoperative plasma levels of B7-family protein homolog 4 (B7-H4), intact and cleaved soluble urokinase plasminogen activator receptor (suPAR), human epididymis protein 4 (HE4) and cancer antigen 125 (CA125) were analyzed in 350 patients with adnexal lesions. Results: The levels of suPAR(II-III), HE4, CA125 were all higher in EOC II than in EOC I, borderline and benign ovarian tumors. B7-H4 was increased in EOC II compared with benign ovarian tumors. The combination of suPAR(II-III), HE4, CA125 and age in premenopausal women discriminates EOC and borderline tumors from benign tumors to higher accuracy compared to the Risk of Ovarian Malignancy Algorithm (p=0.007). Conclusion: The biomarker panel suPAR(II-III), HE4, CA125 and age in premenopausal women improved discrimination of malignant and benign ovarian tumors. The plasma levels of B7-H4 were increased in patients with EOC II compared to those with benign ovarian tumors. ER -